Neuroendocrine Carcinoma has a robust NIH research funding landscape with 29 funded grants and $33.8M in total funding over the period.
4 new grants started in the last 12 months.
1 additional grant classified as “Other” (multi-disciplinary, infrastructure, etc.).
NIH fiscal year (Oct–Sep)
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Neuroendocrine Carcinoma. Strongest funded area: Translational / Drug Development. Largest gap: Epidemiology / Natural History.
11 funded grants in Translational / Drug Development but only 2 related publications found for neuroendocrine carcinoma. This may indicate early-stage research that hasn't yet produced published results.
2 funded grants in Gene Therapy / Cell Therapy but only 2 related publications found for neuroendocrine carcinoma. This may indicate early-stage research that hasn't yet produced published results.
27 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for neuroendocrine carcinoma. Existing research activity suggests this may be a viable area for grant applications.
15 publications in Epidemiology / Natural History but no NIH-funded grants found in Epidemiology / Natural History for neuroendocrine carcinoma. Existing research activity suggests this may be a viable area for grant applications.
These grants mention Neuroendocrine Carcinoma as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.
Track funding opportunities for Neuroendocrine Carcinoma.
Follow this disease to be notified about new NIH grants and funding changes.
Already have an account? Sign in to manage your watchlists.